Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340676 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02340676 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT02340676, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following allogeneic stem cell transplant.
Interventions
- DRUG Interleukin-2
- PROCEDURE Extracorporeal Photopheresis (ECP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-02 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340676
The ClinicalTrials.gov registry entry for NCT02340676 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Interleukin-2 is the first listed.
NCT02340676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02340676 about?
NCT02340676 is a clinical study titled "A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD". This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following allogeneic stem cell transplant.
What is the current status of trial NCT02340676?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-02. Estimated completion is 2025-09.
What interventions are being tested in trial NCT02340676?
The interventions under investigation include: Interleukin-2 (DRUG), Extracorporeal Photopheresis (ECP) (PROCEDURE).
Who is sponsoring clinical trial NCT02340676?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.